Citius Pharmaceuticals, Inc. Reimbursement Revenue (Deprecated 2018-01-31)
Citius Pharmaceuticals, Inc. (CTXR) reported Reimbursement Revenue (Deprecated 2018-01-31) of $292.57 thousand for the 3-month period ending 2016-03-31, per its 10-K filed 2017-12-13.
Discontinued › Income Statement › Other Income
us-gaap:ReimbursementRevenue · last filed 2017-12-13
- Citius Pharmaceuticals, Inc. reimbursement revenue (deprecated 2018-01-31) for the quarter ending 2016-03-31 was $292.57K.
| Period end | Reimbursement Revenue (Deprecated 2018-01-31) 3 month |
|---|---|
| 2016-03-31 | $292.57K 10-K · filed 2017-12-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |